戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 ile of adverse reactions (which are mild and manageable).
2  toxicities with olaparib were low grade and manageable.
3  were reported in 15 (60%) patients and were manageable.
4                 Safety and tolerability were manageable.
5 ects without clinical benefit and keep costs manageable.
6  with additional toxicity that was generally manageable.
7 iving volasertib were mainly hematologic and manageable.
8 xpected AEs were identified and toxicity was manageable.
9 was well tolerated, and infusion events were manageable.
10 vents were identified and toxic effects were manageable.
11 s encouraging, and toxicities were generally manageable.
12 he nephrotoxicities of 3a-c to be clinically manageable.
13  eligible patients and the safety profile is manageable.
14 lenge to keep data load and acquisition time manageable.
15  to cycles of booms and busts, and thus less manageable.
16 ualization of extremely large complexes more manageable.
17           Toxicities were generally mild and manageable.
18         Pregnancy complications were few and manageable.
19 re infrequent and typically asymptomatic and manageable.
20 nfusion-related reactions (IRRs), which were manageable.
21 ted primarily of myelosuppression, which was manageable.
22 emotoxicity complication rate is limited and manageable.
23 troviral therapy, and the disease has become manageable.
24 rombocytopenia, anemia, and neutropenia-were manageable.
25  events (AEs) associated with cediranib were manageable.
26 anemia and peripheral neuropathy, which were manageable.
27 testinal adverse effects and fatigue, proved manageable.
28 ausea, fatigue, and hand-foot syndrome, were manageable.
29                              Toxicities were manageable.
30           Such values are small enough to be manageable.
31    Toxicities were mild to moderate and were manageable.
32  rash, 1% v 0%, respectively), but they were manageable.
33 ologic toxicity was usually grade 1 to 2 and manageable.
34 g number of diseases that are not curable or manageable.
35 de and grade 3 or greater adverse events was manageable.
36 larly in the G-CHOP arm; however, safety was manageable.
37 fe and treatment-related adverse events were manageable.
38 were either transient and resolved or easily manageable.
39    Because these antibodies show only minor, manageable adverse effects in humans, they offer a new t
40              Aldoxorubicin therapy exhibited manageable adverse effects, without unexpected events, a
41                    Four patients experienced manageable adverse effects.
42 partial responses and disease control with a manageable adverse event profile.
43 elinexor induced durable responses and had a manageable adverse events profile in patients with relap
44                        While toxicities were manageable, all patients developed grade 3/4 neutropenia
45  specifying such differences, a rigorous and manageable analytical theory is deduced for the complete
46                              The platform is manageable and affordable even for smaller labs.
47 inib suggested that toxicities are typically manageable and apparent early during drug development.
48   The safety profile of this combination was manageable and consistent with its individual components
49 with weekly paclitaxel was tolerable, with a manageable and distinct toxicity profile.
50 nce-daily (initial dose) on schedule 4-2 was manageable and efficacy results were encouraging, partic
51       Atopic dermatitis is not always easily manageable and every physician should be familiar with t
52 detanib experienced adverse events that were manageable and generally consistent with inhibition of E
53 Foreign physicians described costs that were manageable and high personal satisfaction with STM work.
54    Adverse effects, predominately pain, were manageable and improved with subsequent courses.
55                          Adverse events were manageable and included respiratory tract infections, ga
56       Other adverse effects were mild and/or manageable and most commonly were neutropenia or GI even
57                                 Toxicity was manageable and mostly hematologic, although a few patien
58                                   These were manageable and not generally associated with clinical sy
59 at afford tighter glycemic control in a more manageable and painless manner for patients has remained
60 and glycoproteomics have made the field more manageable and relevant to disease progression and immun
61 ure that contaminant profiles are minimal or manageable and that the same diaper and cotton ball bran
62 a clinically meaningful response rate with a manageable and tolerable safety profile in patients with
63 re unsuitable for intensive chemotherapy was manageable and typical of a cytotoxic agent in patients
64                    These components comprise manageable and widely applicable ways to reduce health-c
65 the number of single step connections can be manageable, and
66 he toxicity profile of VSLI was predictable, manageable, and comparable to standard VCR despite the d
67 obimetinib and vemurafenib was tolerable and manageable, and no new safety signals were observed with
68 cant rate of adverse events (AEs); most were manageable, and PEG discontinuation related to AEs occur
69                                 Toxicity was manageable, and protocol therapy was effective.
70 nique toxicities, the majority are nonfatal, manageable, and reversible.
71 ther prognostic factors that are potentially manageable are prediabetes and the metabolic syndrome, n
72 ocus on the marine benthos where delineating manageable areas for conservation is an attractive prosp
73 rences were nondysplastic and endoscopically manageable, but continued surveillance after RFA is esse
74          These irAEs are often low grade and manageable, but severe irAEs may lead to prolonged hospi
75 sting the protein production rates to levels manageable by available chaperones.
76 ia (44%), and anemia (39%) and was typically manageable by dose reduction.
77 Barr virus reactivation is increased, but is manageable by prospective monitoring and the use of ritu
78  the microbial complexity to be reduced into manageable categories with predictive power.
79 rs (TKIs) have turned a fatal disease into a manageable chronic condition.
80 ent of AIDS, turning a deadly disease into a manageable chronic condition.
81 es to turn a rapidly fatal malignancy into a manageable chronic disease.
82 ncy virus infections from certain death to a manageable chronic disease.
83 e increasing number of survivors of this now manageable chronic illness merits further study.
84 transforming this deadly ailment into a more manageable chronic infection.
85 iagnosis from a likely death sentence into a manageable chronic infection.
86 es the scientific community with an easy and manageable client-server Windows application with graphi
87      We show that our method produces small, manageable clusters that encapsulate many known, experim
88 eatments currently used, as well as identify manageable co-existing factors that could be exacerbatin
89 ession to detect epistatic interactions with manageable complexity by exploiting the prior knowledge
90 le with low mortality and is associated with manageable complication rates.
91 ol after PBT remained good with increasingly manageable complications and fewer secondary enucleation
92 structive pulmonary disease (COPD), a common manageable condition, is a leading cause of death.
93 ave transformed HIV infection into a chronic manageable condition, they do not act upon the latent HI
94 ostate cancer is transformed into a chronic, manageable condition.
95 to be framed as both a serious and medically manageable condition.
96 ve treatments have turned both diseases into manageable conditions, and in the case of hepatitis C, a
97 in a clinically relevant time frame and with manageable costs comes the question of whether we ought
98 ctionated (HDF) cohort had a 90% CR rate and manageable CRS.
99 ysis is fully automated and generates easily manageable databases of standardized fingerprints that c
100 as very low, and the nature of most SAEs was manageable, demonstrating a low-risk safety profile for
101 m a progressive, fatal disease to a chronic, manageable disease marked by elevated risk of chronic co
102 s transformed HIV-1 infection into a chronic manageable disease; however, drug resistance remains a c
103 erapy have rendered HIV infection a chronic, manageable disease; however, the problem of persistent i
104      A successful solution will give rise to manageable enhanced wave-matter interaction, freewheelin
105 ddresses progress in making these approaches manageable for nutrition research.
106 ly expanded ABA core signaling but was still manageable for systematic analysis.
107 ring by making amiRNA a more predictable and manageable genetic and functional genomic technology.
108 tment-emergent adverse events were primarily manageable grade 1/2 gastrointestinal events and rash.
109        pRAIT showed antitumor activity, with manageable hematologic toxicity in progressive MTC.
110  4 infectious episodes or adverse events and manageable hematologic toxicity.
111 ve evolved from toxic, nontargeted agents to manageable, highly targeted therapies.
112 the main toxicities, but they were generally manageable, improved over time, and rarely led to treatm
113             Drug-related adverse effects are manageable in most patients.
114                                 Toxicity was manageable in patients who received maintenance chemothe
115          Time to obtain informed consent was manageable in the clinical context.
116 t ruxolitinib is active, well tolerated, and manageable in the outpatient setting in patients with se
117                                 Toxicity was manageable, including neuropathy in 49 subjects (8% grad
118                       SSRC is safe and has a manageable learning curve.
119 e pool of possible interacting partners to a manageable level for experimental validation.
120 late morbidity in this model to a clinically manageable level.
121 predict that resistance can be maintained at manageable levels if: first, the rates at which specific
122                     These analyses provide a manageable list of candidate genes for future genetic st
123                     The condensation of easy manageable lithium alpha-bis(boryl)carbanions with carbo
124  survival of greater than 2 years, and has a manageable long-term safety profile in patients with rel
125                                              Manageable matrix interference was encountered in pond w
126                               Toxicities are manageable, mostly consisting of mild cytopenias with no
127                              Toxicities were manageable; myelosuppression was the main toxicity (25%
128 d utilizing prioritization rules to ensure a manageable number of 'alarms' each day.
129 plex episodes that could not be reduced to a manageable number of descriptive features with PCA and S
130 ure provides high statistical accuracy and a manageable number of genes to study as indicators to pot
131 ll aid in framing hypotheses to prioritize a manageable number of likely disease-causing SNPs.
132 yelosuppression (48%), although common, were manageable, often leading to dose reductions or interrup
133 ansformed CML from a once-fatal disease to a manageable one for the vast majority of patients, only a
134 orality thus transform into smaller and more manageable ones.
135 us genetic resources for this species into a manageable panel and to provide a uniform methodology th
136                     The lactation stage is a manageable period for improving the health of offspring
137              A design task may be split into manageable pieces in both three-dimensional space and in
138  based on intended levels of specificity and manageable positivity rates.
139 us and Pseudomonas aeruginosa, are generally manageable post-transplantation, and are associated with
140 plexity while operating much faster and with manageable power dissipation, networks based on circuits
141 hich is optimal in environments that present manageable predictive challenges (i.e., reducible uncert
142 onic obstructive pulmonary disease (COPD), a manageable respiratory condition, is the third leading c
143  likely to be associated with acceptable and manageable risks of opportunistic infections associated
144              Anetumab ravtansine exhibited a manageable safety and favorable pharmacokinetic profile
145 These findings suggest that nintedanib has a manageable safety and tolerability profile over long-ter
146 erapy showed durable antitumour activity and manageable safety in patients with metastatic triple-neg
147 lumab demonstrated antitumor activity with a manageable safety profile across the three doses studied
148               Moxetumomab pasudotox showed a manageable safety profile and evidence of activity in re
149                    Durvalumab demonstrated a manageable safety profile and evidence of meaningful cli
150  with CHOP or in combination with CHP, had a manageable safety profile and exhibited substantial anti
151                            Avapritinib has a manageable safety profile and has preliminary antitumour
152 tive targeting of BCL2 with venetoclax had a manageable safety profile and induced substantial respon
153              INTERPRETATION: Nivolumab had a manageable safety profile and no new signals were observ
154  that PD-1 blockade with pembrolizumab has a manageable safety profile and promising antitumor activi
155                  Atezolizumab demonstrated a manageable safety profile and promising antitumor activi
156 Lenvatinib plus pembrolizumab demonstrated a manageable safety profile and promising antitumor activi
157  therapy with nivolumab and ipilimumab had a manageable safety profile and provided clinical activity
158 n BGJ398 at the MTD/RP2D had a tolerable and manageable safety profile and showed antitumor activity
159      Venetoclax with 10-day decitabine has a manageable safety profile and showed high activity in ne
160                 Trastuzumab deruxtecan had a manageable safety profile and showed preliminary activit
161                 Trastuzumab deruxtecan had a manageable safety profile and showed preliminary activit
162 atinib compared with erlotinib, along with a manageable safety profile and the convenience of oral ad
163 py with labetuzumab govitecan demonstrated a manageable safety profile and therapeutic activity in he
164               Conclusion IMGN853 exhibited a manageable safety profile and was active in platinum-res
165 unitinib has shown antitumor activity with a manageable safety profile as metastatic renal cell carci
166 nd a deleterious BRCA alteration, but with a manageable safety profile consistent with that reported
167 ogression-free survival with a tolerable and manageable safety profile in Asian patients with EGFR mu
168  expansion and antileukaemic activity with a manageable safety profile in heavily pretreated paediatr
169 strated clinically meaningful activity and a manageable safety profile in heavily pretreated, double-
170 herapy with robust antitumour activity and a manageable safety profile in patients with BRAF(V600E)-m
171  showed clinically meaningful efficacy and a manageable safety profile in patients with heavily pretr
172 cil and folinic acid extends survival with a manageable safety profile in patients with metastatic pa
173 nically meaningful antitumour activity and a manageable safety profile in patients with previously un
174 enefit versus salvage chemotherapy and had a manageable safety profile in patients with rapidly proli
175 mafodotin shows anti-myeloma activity with a manageable safety profile in patients with relapsed or r
176  high response rate, durable activity, and a manageable safety profile in patients with rrPMBCL.
177 nib is active as single-agent therapy with a manageable safety profile in patients with treatment-nai
178 stantial and durable clinical response and a manageable safety profile in previously treated patients
179 mab has clinically meaningful activity and a manageable safety profile in previously treated patients
180 Dabrafenib plus trametinib was active with a manageable safety profile in this melanoma population th
181      Axitinib shows clinical activity with a manageable safety profile in treatment-naive patients wi
182        Based on the encouraging activity and manageable safety profile observed in a phase 1 study, t
183 potential meaningful clinical activity and a manageable safety profile of isatuximab plus pomalidomid
184                                          The manageable safety profile of this combination and the en
185                                          The manageable safety profile of this drug and the encouragi
186  twice daily showed sustained efficacy and a manageable safety profile over 24 weeks.
187 efractory metastatic urothelial carcinoma; a manageable safety profile was reported in all avelumab-t
188 ave longer progression-free survival, with a manageable safety profile when treated with lenalidomide
189                      Tisotumab vedotin has a manageable safety profile with encouraging preliminary a
190 b in combination with pembrolizumab showed a manageable safety profile with favourable antitumour act
191 ndicates that nilotinib is effective, with a manageable safety profile, and can provide favorable lon
192 onstrated durable tumor control, a generally manageable safety profile, and favorable OS compared wit
193  shown significant clinical activity, with a manageable safety profile, in patients with relapsed or
194   During dose escalation, nivolumab showed a manageable safety profile, including acceptable tolerabi
195 positive NSCLC, and is well tolerated with a manageable safety profile, making it amenable to long-te
196                   Venetoclax plus LDAC has a manageable safety profile, producing rapid and durable r
197 sis of the improved clinical efficacy with a manageable safety profile, the results of this randomise
198 ging single-agent antitumour activity with a manageable safety profile.
199 /refractory AL amyloidosis, with a generally manageable safety profile.
200 ignals identified from the combination and a manageable safety profile.
201 ging single-agent antitumour activity with a manageable safety profile.
202 harmacodynamic biomarker activity, and had a manageable safety profile.
203 ments in progression-free survival and had a manageable safety profile.
204 h active RA over 24 weeks and demonstrated a manageable safety profile.
205 solid tumours, and was well tolerated with a manageable safety profile.
206 f overall response and had an acceptable and manageable safety profile.
207 (V600E)-mutated biliary tract cancer, with a manageable safety profile.
208       Ramucirumab was well tolerated, with a manageable safety profile.
209 th newly diagnosed high-risk mCSPC and had a manageable safety profile.
210 g option, with high antitumor activity and a manageable safety profile.
211 ingful and durable antitumor activity with a manageable safety profile.
212 resistant and HER2-low breast cancer, with a manageable safety profile.
213 t antitumor activity of all regimens, with a manageable safety profile.
214 on-free survival and overall survival with a manageable safety profile.
215 r-risk advanced renal cell carcinoma, with a manageable safety profile.
216                          Both treatments had manageable safety profiles consistent with their known a
217 titumour activity with durable responses and manageable safety profiles in previously treated patient
218 volumab plus ipilimumab therapy demonstrated manageable safety, notable antitumor activity, and durab
219 ti-CSCC activity, with durable responses and manageable safety.
220 ntegrate nanostructures at a larger and thus manageable scale into high performance electronic device
221  to clinically important improvements with a manageable side-effect profile in treatment-naive patien
222    Osimertinib showed clinical activity with manageable side-effects in patients with EGFR Thr790Met-
223  mg trametinib once a day is tolerable, with manageable side-effects.
224 quires their extensive folding into units of manageable size for the mitotic spindle.
225 cause of the need to scale the structures to manageable sizes.
226 y provides a non-optimal but computationally manageable solution to the task of vocal sequence learni
227 e of awareness-before it evolves into a less manageable state.
228  mediator in the progression from clinically manageable steatosis to more severe steatohepatitis and
229 ates the flood of sensory information into a manageable stream, and so understanding how attention is
230 a requires an initial pruning step to create manageable subsets of observations that are then used fo
231           Furthermore, the safety profile is manageable, supporting the use of capecitabine in this s
232 omplex work into the joint effort of several manageable tasks.
233 ts high sensitivity, specificity, yield, and manageable temperature requirements.
234          Adverse events were predictable and manageable; the most common grade 3 or 4 adverse events
235 mon grade 3-4 adverse events were clinically manageable thrombocytopenia (28 [62%] patients) and neut
236          Eribulin demonstrated activity with manageable tolerability (including infrequent grade 3 an
237 icacious, with a low incidence of PTDM and a manageable tolerability profile over 24 weeks of treatme
238 y 4 weeks plus tremelimumab 1 mg/kg showed a manageable tolerability profile, with antitumour activit
239 utated NSCLC compared with gefitinib, with a manageable tolerability profile.
240 -mutated patients, and had an acceptable and manageable tolerability profile.
241  refractory mantle cell lymphoma (MCL), with manageable tolerability.
242 very 28 days-results in clinical benefit and manageable toxic effects.
243 single-group trials that showed efficacy and manageable toxic effects.
244 er, and their combination was active and had manageable toxicities in a phase 1 trial.
245 osutinib demonstrated acceptable safety with manageable toxicities in Ph(+) leukemia.
246        CaboNivo and CaboNivoIpi demonstrated manageable toxicities with durable responses and encoura
247  to oral administration, broad efficacy, and manageable toxicities, miltefosine is a viable alternati
248 reast cancer was feasible, with expected and manageable toxicities.
249 ocetaxel is a highly active combination with manageable toxicities.
250              Therapy was well tolerated with manageable toxicities.
251 and RBV, could increase the rate of SVR with manageable toxicity and drug interactions.
252  that obinutuzumab with either B or FC shows manageable toxicity and has promising activity.
253  ADC brentuximab vedotin was associated with manageable toxicity and induced objective responses in 7
254 ication in HIV/HCV-coinfected patients, with manageable toxicity and pharmacologic interactions with
255              Axitinib plus pembrolizumab has manageable toxicity and preliminary activity in patients
256     Emerging data of clinical studies showed manageable toxicity and safety but limited therapeutic b
257 Pembrolizumab showed antitumour activity and manageable toxicity in early-phase trials.
258 romising single-agent clinical activity with manageable toxicity in patients with relapsed classical
259 produced complete and durable responses with manageable toxicity in patients with relapsed or refract
260  induced complete and durable responses with manageable toxicity in patients with relapsed or refract
261 ity with an overall response rate of 70% and manageable toxicity in patients with relapsed WM and off
262  (40 mg/week), has encouraging activity with manageable toxicity in RRMM, including those refractory
263 tivity in patients with advanced PRCC with a manageable toxicity profile and a high response rate in
264 n with anti-PD-1 monoclonal antibodies had a manageable toxicity profile and preliminary antitumour a
265 positive gastric cancer, pembrolizumab had a manageable toxicity profile and promising antitumour act
266 ollowed by standard-dose pembrolizumab has a manageable toxicity profile and provides robust anti-tum
267 gression-free survival time, combined with a manageable toxicity profile observed with single-agent i
268 gression-free survival time, combined with a manageable toxicity profile observed with single-agent i
269                                 This and the manageable toxicity profile suggest that R-INO may be a
270                The combination therapy had a manageable toxicity profile.
271 l survival (OS) for the eribulin arm, with a manageable toxicity profile.
272 ceived single or fractionated dosing and had manageable toxicity with a 33% complete remission (CR) r
273 nts with indolent non-Hodgkin lymphoma, with manageable toxicity, and is a new treatment option for p
274            Avadomide plus obinutuzumab has a manageable toxicity, being a tolerable treatment option
275 FS compared with FAC therapy, in addition to manageable toxicity, especially regarding long-term card
276 efibrotide was generally well tolerated with manageable toxicity.
277 zantinib was associated with significant but manageable toxicity.
278 therapy produced substantial RCB-0 rate with manageable toxicity.
279 ic responses as well as organ responses with manageable toxicity.
280  survival, and a steroid-sparing effect with manageable toxicity.
281 es, PFS, and TTNT, with expected higher, but manageable toxicity.
282 bimetinib + vemurafenib, had substantial but manageable toxicity.
283 esults AZD1775 plus carboplatin demonstrated manageable toxicity; fatigue (87%), nausea (78%), thromb
284 achieving a major pathological response, and manageable treatment-related toxic effects, which did no
285 This effect raises the possibility that less manageable tumors might also arise in other epithelial t
286 use finite resources can be focussed towards manageable units.
287 iple different populations is a flexible and manageable way to collaboratively integrate widely avail
288 a was the most common adverse effect but was manageable with antidiarrheal agents and dose modificati
289                              Toxicities were manageable with appropriate dose reductions and supporti
290                                  Toxicity is manageable with dose adjustment of sorafenib.
291 drugs is well described and generally easily manageable with dose reductions when indicated.
292 ually restricted to the anterior segment and manageable with local corticosteroid therapy, which just
293 l ipilimumab-induced irAEs that were readily manageable with standard therapies when started in a tim
294                          Adverse events were manageable with supportive care implementation.
295 ointestinal toxicities, which were generally manageable with supportive care.
296                Grade 3-4 adverse events were manageable with the most common being neutropenia (n=10
297 anti-PD-1/PD-L1 therapies and were generally manageable with topical steroids.
298                                 Toxicity was manageable, with 30% of patients experiencing at least 1
299         Toxicity was usually hematologic and manageable, with grade 4 febrile neutropenia in 3% of de
300                    Adverse events (AEs) were manageable without cumulative toxicities.

 
Page Top